ReviewCurrent treatment options in oncology2021
Role of Laser Interstitial Thermal Therapy in the Management of Primary and Metastatic Brain Tumors.
Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Laser interstitial thermal therapy (LITT) for brain metastases: a systematic review and pooled analysis of Efficacy/Safety and the role of combination treatments.Journal of neuro-oncology · 2026Pooled it
- Laser Interstitial Thermal Therapy for High-Grade Gliomas: Current Evidence, Clinical Applications and Emerging Role of Artificial Intelligence.Journal of clinical medicine · 2026Review
- New insights from MRI-guided laser interstitial thermal therapy for refractory epilepsy: a state-of-the-art overview.Frontiers in surgery · 2026Review
- Role of Endoscopic Ultrasound in the Diagnosis and Management of Liver Diseases.Journal of clinical medicine · 2025Review
- Regulation of the brain tumor microenvironment by focused ultrasound.Molecular therapy. Oncology · 2025Review
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Laser interstitial thermal therapy as a radiation-sparing approach for central nervous system tumors in children with cancer predisposition syndromes: report of a child with Li-Fraumeni syndrome. Illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Current status and research progress of minimally invasive treatment of glioma.Frontiers in oncology · 2024Review
- Advancements in Glioma Care: Focus on Emerging Neurosurgical Techniques.Biomedicines · 2023Review
- Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.Cancers · 2023Review
- Modeling andFrontiers in neurology · 2023Article
- Transnasal targeted delivery of therapeutics in central nervous system diseases: a narrative review.Frontiers in neuroscience · 2023Review
- Treatment Modelling of a 3D Tumour in Brain by Laser-Induced Interstitial Thermotherapy.Journal of lasers in medical sciences · 2023Article
- Safety and efficacy of salvage therapy with laser interstitial thermal therapy for malignant meningioma refractory to cesium-131 brachytherapy: illustrative case.Journal of neurosurgery. Case lessons · 2022Article
- Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors.Current oncology (Toronto, Ont.) · 2022Review
- Laser hyperthermia: Past, present, and future.Neuro-oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementLaser interstitial thermal therapy (LITT) is a minimally invasive treatment option for brain tumors including glioblastoma, other primary central nervous system (CNS) neoplasms, metastases, and radiation necrosis. LITT employs a fiber optic coupled laser delivery probe stabilized via stereotaxis to deliver thermal energy that induces coagulative necrosis in tumors to achieve effective cytoreduction. LITT complements surgical resection, radiation treatment, tumor treating fields, and systemic therapy, especially in patients who are high risk for surgical resection due to tumor location in eloquent regions or poor functional status. These factors must be balanced with the increased rate of cerebral edema post LITT compared to surgical resection. LITT has also been shown to induce transient disruption of the blood-brain barrier (BBB), especially in the peritumoral region, which allows for enhanced CNS delivery of anti-neoplastic agents, thus greatly expanding the armamentarium against brain tumors to include highly effective anti-neoplastic agents that have poor BBB penetration. In addition, hyperthermia-induced immunogenic cell death is another secondary side effect of LITT that opens up immunotherapy as an attractive adjuvant treatment for brain tumors. Numerous large studies have demonstrated the safety and efficacy of LITT against various CNS tumors and as the literature continues to grow on this novel technique so will its indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.